Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer

Setsuko K Chambers, R. L. Chopyk, J. T. Chambers, P. E. Schwartz, T. P. Duffy

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy-related leukemia.

Original languageEnglish (US)
Pages (from-to)2459-2461
Number of pages3
JournalCancer
Volume64
Issue number12
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Alkylating Agents
Ovarian Neoplasms
Doxorubicin
Cisplatin
Leukemia
Preleukemia
Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Acute Myeloid Leukemia
Therapeutics
Incidence
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. / Chambers, Setsuko K; Chopyk, R. L.; Chambers, J. T.; Schwartz, P. E.; Duffy, T. P.

In: Cancer, Vol. 64, No. 12, 1989, p. 2459-2461.

Research output: Contribution to journalArticle

Chambers, Setsuko K ; Chopyk, R. L. ; Chambers, J. T. ; Schwartz, P. E. ; Duffy, T. P. / Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. In: Cancer. 1989 ; Vol. 64, No. 12. pp. 2459-2461.
@article{5dd3f514f32948d5b1be40b998b00791,
title = "Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer",
abstract = "Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy-related leukemia.",
author = "Chambers, {Setsuko K} and Chopyk, {R. L.} and Chambers, {J. T.} and Schwartz, {P. E.} and Duffy, {T. P.}",
year = "1989",
doi = "10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T",
language = "English (US)",
volume = "64",
pages = "2459--2461",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer

AU - Chambers, Setsuko K

AU - Chopyk, R. L.

AU - Chambers, J. T.

AU - Schwartz, P. E.

AU - Duffy, T. P.

PY - 1989

Y1 - 1989

N2 - Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy-related leukemia.

AB - Alkylating agents have been the major group of chemotherapeutic agents associated with an increased incidence of secondary leukemias. In ovarian cancer alkylating agents have resulted in a lesser, although still increased, risk of secondary malignancies. This paper reports two cases of ovarian cancer treated with cisplatin and doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), and the subsequent development of an acute nonlymphocytic leukemia and a preleukemia syndrome. This regimen does not contain alkylating agents, and has not been associated with leukemia in patients with ovarian cancer. In these two cases, abnormalities of chromosomes 5, 7, 11, and 17 are reported which have been shown to occur in therapy-related leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0024827183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024827183&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T

DO - 10.1002/1097-0142(19891215)64:12<2459::AID-CNCR2820641210>3.0.CO;2-T

M3 - Article

VL - 64

SP - 2459

EP - 2461

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -